Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs

• Lantheus Holdings Inc (NASDAQ: LNTH) has licensed POINT Biopharma Global Inc's (NASDAQ: PNT) PNT2002 and PNT2003 product candidates.

• Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on FDA approval and net sales and commercial milestones.

• Additionally, Lantheus will pay POINT royalties on net sales of 20% for PNT2002 and 15% for PNT2003.

• The agreements expand Lantheus' radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus' prostate cancer franchise.

• PNT2002 is a PSMA-targeted 177Lu-based radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC).

• PNT2002 is currently in its Phase 3 study designed to evaluate superiority to the standard of care in mCRPC pre-chemotherapy patients who have failed one androgen receptor pathway inhibitor.

• PNT2003 is a somatostatin receptor (SSTR) targeted radioligand therapy with no-carrier-added 177Lu, in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PNT2003 is currently in a Phase 3 trial.

• Price Action: PNT shares are down 34.6% at $5.98, and LNTH shares are up 0.02% at $56.48 on the last check Monday.

See more from Benzinga

• At Higher Dose, Viridian's Thyroid Eye Disease Candidate Shows Significant, Rapid Improvement In Signs & Symptoms

• Moderna Says Omicron Tailored COVID-19 Shots Shows Better Immune Response Than Original Vaccine

• Elon Musk Asked A Top Tesla Executive To Forfeit Unvested Equity Awards And He Promptly Quit: Report - Te

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.